These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38616616)

  • 1. Sailing in deceptive calm: Navigating the undercurrents of essential thrombocythaemia.
    Hashimoto Y; Lucchesi A
    Br J Haematol; 2024 May; 204(5):1595-1597. PubMed ID: 38616616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.
    Ferrer-Marín F; Hernández-Boluda JC; Alvarez-Larrán A
    Br J Haematol; 2024 May; 204(5):1605-1616. PubMed ID: 38586911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort.
    Michail O; McCallion P; McGimpsey J; Hindley A; Greenfield G; McAllister R; Feerick J; Arnold C; Cross N; Cuthbert R; McMullin MF; Catherwood MA
    J Clin Pathol; 2021 Dec; 74(12):808-811. PubMed ID: 33144355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next generation sequencing redefines a triple negative essential thrombocythaemia as double-positive with rare mutations on JAK2 V617 and MPL W515 hotspots.
    Beucher A; Dib M; Orvain C; Bouvier A; Jouanneau-Courville R; Dobo I; Cottin L; Guardiola P; Rousselet MC; Blanchet O; Hunault M; Ugo V; Luque Paz D
    Br J Haematol; 2019 Sep; 186(5):785-788. PubMed ID: 31087331
    [No Abstract]   [Full Text] [Related]  

  • 5. Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort.
    Randi ML; Geranio G; Bertozzi I; Micalizzi C; Ramenghi U; Tucci F; Notarangelo LD; Ladogana S; Menna G; Giordano P; Consarino C; Farruggia P; Zanazzo GA; Fiori GM; Burnelli R; Russo G; Jankovich M; Peroni E; Duner E; Basso G; Fabris F; Putti MC
    Br J Haematol; 2015 May; 169(4):584-9. PubMed ID: 25716342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory Arterial Insufficiency Associated with Janus Kinase 2 Positive Essential Thrombocythaemia.
    Sivakumaran Y; Freeman A
    Ann Vasc Surg; 2017 Jan; 38():317.e13-317.e16. PubMed ID: 27531097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in
    Pan Y; Wang X; Wen S; Liu X; Yang L; Luo J
    Hematology; 2022 Dec; 27(1):902-908. PubMed ID: 36000955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation.
    Torregrosa JM; Ferrer-Marín F; Lozano ML; Moreno MJ; Martinez C; Anton AI; Rivera J; Vicente V
    Br J Haematol; 2016 Mar; 172(5):813-5. PubMed ID: 26132594
    [No Abstract]   [Full Text] [Related]  

  • 9. Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms.
    Kucine N; Al-Kawaaz M; Hajje D; Bussel J; Orazi A
    Br J Haematol; 2019 Apr; 185(1):136-139. PubMed ID: 29767848
    [No Abstract]   [Full Text] [Related]  

  • 10. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
    Lewandowski K; Kanduła Z; Gniot M; Paczkowska E; Nawrocka PM; Wojtaszewska M; Janowski M; Mariak M; Handschuh L; Kozlowski P
    Ann Hematol; 2022 Dec; 101(12):2665-2677. PubMed ID: 36266510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeat
    Kearney L; Lee Tokar L; Flynn C; Mykytiv V; Murphy K; Langabeer SE
    J Clin Pathol; 2020 Nov; 73(11):772. PubMed ID: 32646925
    [No Abstract]   [Full Text] [Related]  

  • 12. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia.
    Wong RS; Cheng CK; Chan NP; Cheng SH; Wong WS; Lau KM; Cheng G; Ng MH
    Br J Haematol; 2008 Jun; 141(6):902-4. PubMed ID: 18410451
    [No Abstract]   [Full Text] [Related]  

  • 14. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.
    Trifa AP; Popp RA; Cucuianu A; Bănescu C; Tevet M; Martin B; Murat M; Vesa SC; Dima D; Cândea M; Militaru MS; Pop IV
    Br J Haematol; 2015 Jan; 168(1):151-3. PubMed ID: 25103987
    [No Abstract]   [Full Text] [Related]  

  • 15. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
    Andrikovics H; Krahling T; Balassa K; Halm G; Bors A; Koszarska M; Batai A; Dolgos J; Csomor J; Egyed M; Sipos A; Remenyi P; Tordai A; Masszi T
    Haematologica; 2014 Jul; 99(7):1184-90. PubMed ID: 24895336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.
    Lussana F; Caberlon S; Pagani C; Kamphuisen PW; Büller HR; Cattaneo M
    Thromb Res; 2009 Sep; 124(4):409-17. PubMed ID: 19299003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular heterogeneity unravelled by single-cell transcriptomics in patients with essential thrombocythaemia.
    Hsu CC; Chen YJ; Huang CE; Wu YY; Wang MC; Pei SN; Liao CK; Lu CH; Chen PT; Tsou HY; Li CP; Chuang WH; Chuang CK; Yang CY; Lai YH; Lin YH; Chen CC
    Br J Haematol; 2020 Mar; 188(5):707-722. PubMed ID: 31610612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1.
    Al Assaf C; Lierman E; Devos T; Billiet J; Graux C; Papadopoulos P; Vandenberghe P
    Br J Haematol; 2014 Jun; 165(5):734-7. PubMed ID: 24611479
    [No Abstract]   [Full Text] [Related]  

  • 19. [Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
    Krähling T; Balassa K; Meggyesi N; Bors A; Csomor J; Bátai Á; Halm G; Egyed M; Fekete S; Reményi P; Masszi T; Tordai A; Andrikovics H
    Orv Hetil; 2014 Dec; 155(52):2074-81. PubMed ID: 25528320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.
    Yang Y; Wang X; Wang C; Qin Y
    Int J Hematol; 2015 Feb; 101(2):165-72. PubMed ID: 25540065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.